Your Complete Policy Management Partner
Everything your healthcare organization needs to confidently maintain accreditation compliance.
Robust document control and workflow management software solution
Simplify & automate policy access, review and approval across your organization
Web-based library of more than 18,000 customizable policy documents
Instantly access up-to-date policies, procedures & forms authored by MCN experts
Automated regulatory notification system of daily email or mobile alerts
Keep current with regulatory changes from more than a dozen federal regulatory bodies, including TJC & NIAHO
What Our Customers are Saying
MCN Healthcare has been indispensable to our accreditation compliance efforts. With Policy Manager, Policy Library and StayAlert!, we have peace of mind that our policies will always be up-to-date and easy to locate.
Beverly McKenzie, Compliance Programs Director, IASIS Healthcare
Helpful MCN Healthcare Resources
The US Centers for Disease Control and Prevention (CDC) is reporting that more than a third of reproductive-aged women enrolled in Medicaid, and more than a quarter of those with private insurance, filled a prescription for an opioid pain medication each year during 2008-2012. "These statistics are alarming because of the fact that taking opioid medications early in pregnancy can cause birth defects and serious problems for the infant and the mother, and many women of reproductive age are taking these medicines and may not know they are pregnant and therefore may be unknowingly exposing their unborn child. "
According to the CDC it is critical for health care professionals to take a thorough health assessment before prescribing these medicines to women of reproductive age.
The CDC researchers analyzed 2008-2012 data from two large health insurance claims data sets: one of women aged 15-44 years with private insurance and another of women in the same age group enrolled in Medicaid. They found that on average, 39 percent of Medicaid-enrolled women filled an opioid prescription from an outpatient pharmacy each year compared to 28 percent of women with private health insurance.
Previous studies of opioid use in pregnancy suggest these medications might increase the risk of neural tube defects, congenital heart defects and gastroschisis. There is also a risk of neonatal abstinence syndrome (NAS) from exposure to medications such as opioids in pregnancy. NAS is when a newborn experiences symptoms of withdrawal from medications or drugs taken by a mother during pregnancy.
The CDC's National Center on Birth Defects and Developmental Disabilities is working to provide better information to women and their health care providers about medication use during pregnancy through its Treating for Two: Safer Medication Use in Pregnancy initiative. Follow the link below for additional information.
Review of Joint Commission New and Revised Elements of Performance for Diagnostic Imaging Services, Effective July 1, 2015 â€“ Part Four
This is the fourth in a series of StayAlert! Notices' reviewing The Joint Commission's (TJC) recently released new and revised elements of performance (EPs) for their Diagnostic Imaging Services requirements. The changes are applicable to accredited hospitals, critical access hospitals and ambulatory health care facilities that provide diagnostic imaging services and are effective July 1, 2015.
TJC has added elements of performance to Human Resources Standard.01.05.03 for hospitals and critical access hospitals. This standard requires organizations to ensure that staff participate in ongoing education and training. New EP's for this standard require that:
- The organization verifies and documents that ongoing training and education for technologists who perform diagnostic computed tomography (CT) examinations includes the following:
o Radiation dose optimization techniques and tools for pediatric and adult patients addressed in the Image Gently® and Image Wisely® campaigns.
o Safe procedures for operating each type of CT equipment the technologist will use.
- The organization verifies and documents that technologists who perform magnetic resonance imaging (MRI) examinations participate in ongoing education that includes annual training on safe MRI practices in the MRI environment, including:
o Patient screening criteria that address ferromagnetic items, electrically conductive items, medical implants and
devices, and risk for Nephrogenic Systemic Fibrosis (NSF).
o Techniques to avoid thermal injuries including proper patient and equipment positioning.
o MR safe or MR conditional equipment and supplies.
o MRI safety response procedures for patients who require urgent or emergent medical care.
o MRI system emergency shutdown procedures, such as MRI system quench and cryogen safety procedures.
o Patient hearing protection.
o Management of patients with claustrophobia, anxiety, or emotional distress.
Included with today's notice are example policies that reflect these changes.
FDA Issues Safety Communication about Bone Graft Substitutes Containing Recombinant Proteins or Synthetic Peptides in Patients Under Age 18
The US Food and Drug Administration (FDA) is aware of healthcare providers using bone graft substitutes containing recombinant proteins or synthetic peptides in patients under age 18. Reports of serious injuries, such as excess bone growth, fluid accumulation, inhibited bone healing, and swelling, have increased the FDA's concern. The FDA considers bone graft substitutes containing recombinant proteins or synthetic peptides high-risk (Class III) medical devices. Before marketing the products, manufacturers are required to submit a premarket approval application (PMA) that includes clinical data supporting safety and effectiveness. The FDA has not evaluated their safety and effectiveness in patients under age 18.
While these types of events are similar to those seen in patients over age 18, they are of more concern in patients under age 18 because of their overall smaller size and because their bones are still growing. Any product that affects bone growth could have the potential to negatively impact skeletal development by altering normal bone formation and growth, especially if implanted near open growth plates.
- The FDA recommends against routine use of these products in patients under age 18 because their safety and effectiveness has not been reviewed or approved for use in this population.
- Consider alternatives such as autograft bone, allograft bone, and bone graft substitutes that do not contain recombinant proteins or synthetic peptides before using bone graft substitutes containing recombinant proteins and synthetic peptides in patients under age 18.
- Carefully consider the benefits and risks before using these products in any patient. If considered the best or only option, inform parents/guardians and patients about the risks and benefits of using the product when discussing surgical options.
- Closely monitor patients under age 18 for adverse events and if necessary, refer them to the appropriate healthcare provider for corrective treatment. Adverse events may include problems with skeletal development, excess growth of other tissues, and tissue swelling or fluid accumulation that could put pressure on adjacent organs or tissues.
See the FDA Safety Communication for additional recommendations for parents, guardians, and patients.
Featured Policy Library Manuals
MCN’s Utilities and Equipment Management Policy and procedure Manual is a reference guide that is compliant with Joint Commission, NIAHO and CIHQ standards and CMS regulations. MCN provides easy-to-use policies and procedures that are field tested and proven - you need only to customize them to your healthcare organization. Policies and procedures include Utility Systems Management Plan, Alternative Equipment Maintenance Program, Clinical Alarms, Emergency Power and much more!Read more »
MCN Healthcare’s Administrative Manual for Critical Access Hospitals is specifically designed to assist critical access hospitals meet CMS, TJC and NIAHO standards for CAHs. This manual provides over 275 ready-to-implement policies, procedures and forms in an easy-to-customize Word format, and is designed to demonstrate compliance with CAH regulations. Transplant Safety polices are also included in this manual.Read more »
MCN's NEW Ambulatory Surgical Center/Outpatient Surgery Department Policy and Procedure Manual is cross referenced to TJC standards, AAAHC standards and CMS regulations. Policies and procedures meet AORN and CDC recommendations and guidelines. This comprehensive reference guide has over 290 policies and procedures that are ready to customize to your organization. See also the Administrative Manual for Ambulatory Care Facilities and the Ambulatory Services EOC Manual.Read more »